Literature DB >> 2690260

Paraneoplastic and serologic syndromes of renal adenocarcinoma.

G Sufrin1, S Chasan, A Golio, G P Murphy.   

Abstract

In renal carcinoma, the inappropriate, unscheduled, or aberrant production of hormones and other serologic markers and the resulting clinical or biochemical syndromes are unique manifestations of this tumor. The elaboration of biologically active factors by renal adenocarcinoma may add a metabolic burden to an already compromised host, and thus affect therapy and prognosis; they should be considered before ascribing symptoms to metastasis or dissemination. Similarly it has been suggested that the elaboration of biologically-inactive peptides and proteins is a very common concomitant of neoplasia and the identification of such factors may facilitate earlier diagnosis and novel therapies in patients with renal carcinoma.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2690260

Source DB:  PubMed          Journal:  Semin Urol        ISSN: 0730-9147


  5 in total

Review 1.  Tumors of the kidney, ureter, and bladder.

Authors:  W A See; R D Williams
Journal:  West J Med       Date:  1992-05

2.  Renal cell carcinoma and arterial hypertension.

Authors:  Milan Stojanovic; Branislav Goldner; Dusan Ivkovic
Journal:  Clin Exp Nephrol       Date:  2009-01-29       Impact factor: 2.801

3.  [Superior vena cava syndrome with bilateral jugular and subclavian vein thrombosis. Paraneoplastic manifestion of renal cell carcinoma].

Authors:  M May; M Seehafer; C Helke; T Uberrück; S Gunia; B Hoschke
Journal:  Urologe A       Date:  2003-10       Impact factor: 0.639

4.  Erythrocyte sedimentation rate and anaemia are independent predictors of survival in patients with clear cell renal cell carcinoma.

Authors:  Y Choi; B Park; K Kim; B C Jeong; S I Seo; S S Jeon; H Y Choi; J E Lee; H M Lee
Journal:  Br J Cancer       Date:  2013-01-08       Impact factor: 7.640

5.  In Vitro and In Vivo (1)H-MR Spectroscopic Examination of the Renal Cell Carcinoma.

Authors:  F Süllentrop; J Hahn; D Moka
Journal:  Int J Biomed Sci       Date:  2012-06
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.